School of Medicine
Showing 1-50 of 77 Results
-
Laura Michele Hack
Assistant Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences)
BioDr. Laura Hack is an Assistant Professor in the Department of Psychiatry and Behavioral Sciences, Director of Novel & Precision Neurotherapeutics at the Stanford Center for Precision Mental Health and Wellness, Director of the Stanford Translational Precision Mental Health Clinic, and Deputy Director of the Precision Neuromodulation Clinic (PNC) within the VA Palo Alto Health Care System. Dr. Hack's translational research program focuses on identifying bioclinical subtypes of depression and testing mechanistically-guided treatments for these subtypes. Dr. Hack studies treatments spanning repurposed medications, such as pramipexole and guanfacine, neuromodulation techniques, ketamine, MDMA, and psilocybin. Clinically, she specializes in delivering novel treatments, including repetitive transcranial magnetic stimulation (rTMS) and ketamine, to patients suffering from treatment-resistant depression and comorbid trauma-related disorders.
-
Scott S. Hall, Ph.D
Professor of Psychiatry and Behavioral Sciences (Interdisciplinary Brain Sciences)
Current Research and Scholarly InterestsMy primary area of scholarly and clinical interest is the pathogenesis of problem behaviors shown by individuals diagnosed with intellectual and developmental disabilities (IDD), particularly those with neurogenetic forms of IDD, such as fragile X syndrome, Cornelia de Lange syndrome and Prader-Willi syndrome. My work aims to both advance understanding of these disorders and to identify effective new treatment approaches for pediatric and adult patient populations by state-of-the-art methodologies, such as brain imaging, eye tracking and functional analysis to determine how environmental and biological factors affect the development of aberrant behaviors in these syndromes. The end goal of my research is to create patient-specific methods for treating the symptoms of these disorders.
-
Haijing Wu Hallenbeck
Instructor (Affiliated), Psych/Public Mental Health & Population Sciences
Staff, Psych/Public Mental Health & Population SciencesBioHaijing Hallenbeck, PhD, is a research investigator at the National Center for PTSD Dissemination & Training Division at VA Palo Alto Health Care System. She is also an Instructor (Affiliated) in the Department of Psychiatry and Behavioral Sciences at Stanford University School of Medicine. She received her PhD in Clinical Psychology from Washington University in St. Louis and completed her predoctoral clinical internship and postdoctoral research fellowship at VA Palo Alto Health Care System. Funded by the VA VISN 21 Early Career Award Program, Dr. Hallenbeck's research focuses on PTSD and depression and their impact on psychosocial functioning. She studies how to leverage digital health technology (e.g., mobile apps) and analytic tools (e.g., machine learning) to provide timely and personalized assessments and interventions for these conditions.
Email: haijing.hallenbeck@stanford.edu -
Joachim Hallmayer
Professor of Psychiatry and Behavioral Sciences
Current Research and Scholarly InterestsPrincipal Investigator
Infrastructure to facilitate discovery of autism genes
The purpose of this project is to facilitate the discovery of the genes that contribute autism by maintaining an infrastructure which research groups studying the genetics of autism can work collaboratively. This will be
accomplished through workshops, a Virtual Private Network, and access to a database that includes phenotype and genotype data from all participating groups.
Principal Investigator
A California Population-Based Twin Study of Autism
This will address several fundamental questions: (1) What is the heritability of autism (2) What is the contribution of genetic factors to variation in symptom dimensions? (3) Is there a continuum between the quantitative neurocognitive traits and clinical disorder? (4) What proportion of the variance in the neurocognitive traits is accounted for by genetic and non-genetic factors?
Co-Investigator
Center for Integrating Ethics in Genetics Research(Cho)
The goal of this project is to serve as a center of excellence in neurogenetics research, to develop a national model for bench, to bedside research ethics consultation, and to provide training opportunity in biomedical ethics.
Co-Investigator
Gene, Brain and Behavior in Turner Syndrome(Reiss)
The primary objective of this project is to use advanced, multi-modal magnetic resonance imaging (MRI) techniques, analyses of X chromosome parent-of-origin and cognitive-behavioral assessment to elucidate the effects of monosomy and X-linked imprinting on neurodevelopment and neural function in a large cohort of young girls with Turner syndrome, pre-estrogen replacement.
Project Director
Project F: Genomic Analysis in narcolepsy cataplexy
The goal of the project is to locate genes outside the HLA region that influence susceptibility to narcolepsy. In order to localize these genes we will carry out a linkage and association study in the most extensive world-wide collection of DNAs from well-characterized patients with narcolepsy and their families. -
Bonnie Halpern-Felsher
Marron and Mary Elizabeth Kendrick Professor of Pediatrics and Professor, by courtesy, of Epidemiology and Population Health and of Psychiatry and Behavioral Sciences
Current Research and Scholarly InterestsResearch focuses on developmental, cognitive and psychosocial factors involved in adolescents’ and young adults’ health-related decision-making, perceptions of risk and vulnerability, health communication and risk behavior. My research has focused on understanding and reducing health risk behaviors such as tobacco use, alcohol and marijuana use, risky driving, and risky sexual behavior.
-
Mindy Hantke
Public Rel Offcr 2, Psychiatry and Behavioral Sciences
Current Role at StanfordWeb & Communications Administration
-
Antonio Hardan, M.D.
Professor of Psychiatry and Behavioral Sciences
Current Research and Scholarly InterestsThe neurobiology of autism
Neuroimaging in individuals with autism
Psychopharmacological treatment of children and adults with autism and/or developmental disorders
The neurobiology and innovative interventions of several neurogenic disorders including DiGeorge Syndrome (Velocardiofacial syndrome; 22q11.2 mutations), PTEN mutations, and Phelan McDermid Syndrome (22q13 mutations). -
Kate Hardy
Clinical Professor, Psychiatry and Behavioral Sciences
BioKate Hardy is a California Licensed Psychologist who has specialized in working with individuals with psychosis for over 15 years in both research and clinical settings. Dr. Hardy received her doctorate in clinical psychology from the University of Liverpool, United Kingdom. She has worked in specialist early psychosis services in both the UK and the US, including UCSF’s Prodrome Assessment Research and Treatment (PART) program, where she completed her post-doctoral fellowship, and as Clinical Director for the Prevention and Recovery from Early Psychosis (PREP) program. Dr. Hardy has significant experience in providing CBTp to individuals with early psychosis, and those at risk of developing psychosis, in both individual and group settings and integration of this clinical intervention to broader systems and staff teams. She has led multiple trainings and workshops in CBTp to a wide variety of audiences including community clinicians, psychiatrists, and families, and provides ongoing supervision and consultation in this approach. Dr. Hardy is also involved in the implementation of national strategies to increase dissemination of early psychosis models with the aim of bringing these cutting edge treatments to a broader population.
-
Nancy A. Haug
Adjunct Clinical Professor, Psychiatry and Behavioral Sciences
BioNancy A. Haug, PhD is Adjunct Clinical Professor and Addiction Medicine fellowship program faculty in the Department of Psychiatry and Behavioral Sciences at Stanford University School of Medicine. She currently leads didactics and a journal club for Addiction Medicine fellows, and teaches a postdoctoral seminar on ethics and legal issues for the Clinical Psychology Fellowship Program. Dr. Haug's primary academic affiliation is Professor of Psychology at Palo Alto University, where she teaches, advises and supervises doctoral students in the PGSP-Stanford PsyD Consortium. Dr. Haug previously served as faculty and attending psychologist in the Department of Psychiatry at the University of California San Francisco, and taught in the University of California, Berkeley Alcohol & Drug Studies program. She obtained her PhD in Clinical Psychology and Behavioral Medicine at the University of Maryland, Baltimore County and a Master's degree in Counseling Psychology at Loyola University, Maryland. She completed a clinical internship and postdoctoral fellowship at University of California, San Francisco and San Francisco General Hospital in public service and minority mental health.
Dr. Haug is a member of the American Psychological Association (APA) Ethics Committee and formerly served as a member of the California Psychological Association Ethics Committee. She is a Fellow and Member-at-Large for Practice in the Society of Addiction Psychology (APA, Division 50). Dr. Haug is on the editorial board of the Journal of Psychoactive Drugs and the Journal of Addictive Diseases. She was funded by SAMHSA for a practitioner-education initiative to expand training for evidence-based addiction treatment. Dr. Haug leads the Harm Reduction and Addiction Treatment Laboratory at PAU with current research studies on the implementation of evidence-based practices in addiction treatment, harm reduction for substance use, cannabis vaping and psychedelic-assisted psychotherapy.
Dr. Haug has been licensed as a psychologist in California since 2004, is board certified in addiction psychology by American Board of Professional Psychology, and has an independent practice in Los Gatos, CA. She has clinical expertise in treating substance misuse and eating disorders using motivational interviewing, cognitive-behavioral and mindfulness-based therapies including Acceptance and Commitment Therapy. Dr. Haug is a Stanford WellConnect referral for fellows, residents and faculty in her clinical practice. She recently completed the Stanford YogaX 200-Hour Yoga Teacher Training Program with healthcare setting emphasis. -
Alesha Heath
Basic Life Res Scientist, Psych/Public Mental Health & Population Sciences
BioDr. Alesha Heath is a Postdoctoral Scholar at Psychiatry and Behavioral Sciences at Stanford School of Medicine and the MIRECC the VA Palo Alto. She earned her PhD from the University of Western Australia and Sorbonne University.
Dr. Heath's research has been primarily focused on the mechanisms and applications of brain stimulation therapies, in particular repetitive transcranial magnetic stimulation. Her research involves both basic and clinical components with the aim of improving the efficacy of these therapies for the treatment of disorders such as depression and Alzheimer's disease. -
Katherine (Heflin) Hefcart
Affiliate, Dean's Office Operations - Dean Other
Resident in Psychiatry and Behavioral SciencesBioAdult Psychiatry PGY1, focuses on Community/Public advocacy and reproductive mental health. Attended Stanford undergraduate ('11), Harvard T.H. Chan School of Public Health ('15), Dartmouth Geisel Medical School ('23).
-
John P. Hegarty II
Clinical Assistant Professor, Psychiatry and Behavioral Sciences
BioI am a neuroscientist and Principal Investigator of the Stanford Clinical Neuroscience (CNS) Lab in the Department of Psychiatry and Behavioral Sciences as well as Director of Neuroimaging for the Autism and Developmental Disorders Research Program at Stanford. My innovative research studies clinical aspects of cognitive and behavioral neuroscience, with a special focus on examining the neural circuitry associated with important brain-behavior relationships that may underlie different psychological and psychiatric domains in autistic children, adolescents, and adults. The ultimate goal of this research is to improve our understanding of the development of different cognitive and behavioral skills in order to develop mechanistically driven interventions that will improve precision medicine for mental health. Biologically based diagnosis and treatment are extremely limited for most psychological and psychiatric conditions but also critically needed to increase early identification and improve treatment outcomes, especially for neurodevelopmental disorders in which early intervention is the most beneficial. My early career research has primarily focused on clinical neuroscience using neuroimaging (e.g., MRI & EEG) to examine the effects of different drugs and behavioral interventions on the brain, especially for developing biomarkers for improving treatment planning and monitoring biological changes in response to single dose and clinical trials.
My primary contributions to science thus far fall within these major categories: 1) identifying the neural correlates of individual differences in cognition and behavior, 2) developing new interventions and investigating the neurobiological substrates of response to treatment, 3) examining different factors that contribute to brain development, 4) summarizing and increasing accessibility to autism-related research, and 5) methods development for neuroimaging studies. My earliest research investigated the neurobiology of alexithymia, dyslexia, and stress using structural and functional magnetic resonance imaging to test theories of the mechanisms that contribute to differences in cognition and behavior. My subsequent dissertation research, in which I began to focus on neurodevelopmental disorders, examined the neural correlates of response to beta-blockers in autistic adults and also assessed the contribution of cerebellar circuits to the autism phenotype. During my postdoctoral training, I have developed further skills for working with children in multiple clinical research settings, especially for using advanced neuroimaging approaches to examine important brain-behavior relationships. This includes a recent K99/R00 from the National Institute of Child Health and Human Development (NCT04278898 & NCT05664789) that will assess the neurobiology of restricted and repetitive behaviors in autistic children and examine the efficacy and target engagement of a novel nutritional supplement and investigational drug, N-acetylcysteine (NAC), in the brain. You can find more information about our NAC studies at https://redcap.link/NACandAutism. -
Kimberly Hill
Clinical Professor, Psychiatry and Behavioral Sciences
BioDr. Hill received her Ph.D. in Clinical Psychology from Ohio University. She completed her doctoral internship at the Veterans Affairs Palo Alto Health Care System and postdoctoral fellowship in the Psychiatry Department at the Stanford University School of Medicine where she currently serves as a Clinical Professor. Dr. Hill has published articles and made presentations related to psychology training, pain management, serious mental illness including Post Traumatic Stress Disorder, and sexual dysfunction.
Dr. Hill's time is divided across clinical, research, administrative, and teaching domains. Her current clinical interests are varied including anxiety, mood disorders, relationship difficulties, and post-traumatic stress disorder. The bulk of her time is committed to psychology training as the Director of Clinical Training for the PGSP-Stanford Psy.D. Consortium. On a national level, she currently serves as the Vice Chair of the Association of Psychology Postdoctoral and Internship Centers (APPIC). -
Rachel Hilton
Casual - Non-Exempt, Psych/Major Laboratories and Clinical & Translational Neurosciences Incubator
Current Role at StanfordResearch Nurse Practitioner- Precision Psychiatry for Williams PanLab, Department of Psychiatry and Behavioral Sciences- Stanford University
-
Kyle Hinman, M.D.
Clinical Assistant Professor, Psychiatry and Behavioral Sciences - Child & Adolescent Psychiatry and Child Development
Current Research and Scholarly InterestsAutism, Bipolar Disorder
-
Melanie Hom
Clinical Assistant Professor, Psychiatry and Behavioral Sciences
BioDr. Melanie Hom is a Clinical Assistant Professor and attending psychologist in the Anxiety and Depression Adult Psychological Treatment (ADAPT) Clinic, Dialectical Behavior Therapy (DBT) Clinic, and Stanford Mental Health for Asians Research and Treatment (SMHART) Clinic. She utilizes evidence-based therapies, including acceptance and commitment therapy (ACT), cognitive behavioral therapy (CBT), and DBT. Dr. Hom also strives to provide culturally informed psychotherapy in her work with individuals, couples, and families. Her research interests include (1) enhancing help-seeking and treatment engagement among individuals at elevated suicide risk and (2) improving mental health care services for Asians and Asian Americans.
-
Hamed Honari
Postdoctoral Scholar, Psychiatry
Current Research and Scholarly InterestsMachine Learning, Neuroimaging, Computer Vision,Deep Learning, Signal Processing
-
David S. Hong
Associate Professor of Psychiatry and Behavioral Sciences (Interdisciplinary Brain Science Research)
Current Research and Scholarly InterestsDr. Hong is a child and adolescent psychiatrist and clinician-scientist. His responsibilities span clinical care, teaching/mentorship, and research, with a unifying theme of advancing a developmental cognitive framework as applied to psychiatric conditions. Using this core premise, he work encompasses multiple domains: specialized clinical care, fellowship training, research mentorship, and elaborating the role of sex-specific determinants of development, one of the greatest contributors to individual developmental variation.
His lab investigates genetic and hormonal influences underlying sex differences in child psychiatric conditions. Sex has emerged as a critical variable driving differences in the phenomenology, course, and treatment of many mental health disorders. Unfortunately, an understanding of the biological mechanisms driving these effects are limited. By applying innovative neuroimaging and multiomic approaches, Dr. Hong seeks to provide a deeper understanding of the connection between sex-specific effects and complex psychiatric diseases. To do so, research in the Hong Lab focuses on the role of genes on the X and Y chromosomes, as well as circulating sex hormones on brain development, cognition, and behavior. The lab broadly aims to elucidate the changing nature of these mechanisms across various stages of development.
Another area of focus is the implementation of clinical informatics in child psychiatry and the development of digital mental health tools. As co-Director of the Mental Health Technology and Innovation Hub, Dr. Hong is helping to develop clinical and research infrastructure within the Department of Psychiatry and Behavioral Sciences to advance development of mobile mental health resources that will improve efficacy and access to mental health care. -
Janie Hong, Ph.D.
Clinical Associate Professor, Psychiatry and Behavioral Sciences
BioDr. Hong is invested in developing evidence-based ways to individualize care and address diversity factors in therapy and in training fellows and residents in these approaches. She has published and presented widely on these and other topics in psychology.
In clinical practice, she specializes in providing cognitive behavior therapy (CBT) and other evidence based treatments. She is also committed to helping neurodiverse and culturally diverse individuals work with their differences, navigate prevailing social norms, and advocate for their needs as diverse individuals. -
Korey Hood
Professor of Pediatrics (Endocrinology) and of Psychiatry and Behavioral Sciences (Child and Adolescent Psychology)
BioDr. Hood directs NIH- and foundation-funded clinical research aimed at promoting health and quality of life outcomes for people with diabetes. He has expertise and experience with diabetes epidemiology and interventions, study design, methodology, data management, and advanced statistical methods. There are two content threads to his work: 1) construct prevention and treatment programs to address modifiable psychological and family factors that create barriers to optimal diabetes management, and 2) optimize the use of devices and technologies to improve health outcomes. With regard to the first thread, Dr. Hood has successfully implemented depression screening programs in tertiary diabetes and GI clinics within a Quality Improvement framework, and recently completed a large scale clinical trial on a distress prevention program for teens with type 1 diabetes. Dr. Hood manages and analyzes all the data from these studies. From a device and technology standpoint, Dr. Hood coordinates the Human Factors assessments in Drs. Maahs’ and Buckingham’s closed loop studies and is recognized as one of the experts in this area nationally and internationally. In addition, he has implemented Human Factors assessments in national (e.g., T1D Exchange) studies and registries and is the lead psychologist on 2 of the 4 UC4 grants from NIDDK (Hovorka, PI; Bergenstal, PI). These assessments focus on uptake of devices and technologies, and determining strategies to promote uptake and optimize their use. Dr. Hood and his research team have published over 100 scientific articles on these topics and are active presenters at diabetes, behavioral medicine, and advocacy conferences.
Dr. Hood also works in clinical and service settings. Dr. Hood is a licensed clinical psychologist and is part of the diabetes care team at Stanford. He is the past chair of the American Diabetes Association’s Behavioral Medicine and Psychology Interest Group and is currently a member of the Research Policy Committee. He was also a member of the ADA’s Call to Congress in March 2017. Dr. Hood is an Associate Editor for both Diabetes Care and Pediatric Diabetes. -
Benjamin Joseph Hoover
Clinical Assistant Professor, Psychiatry and Behavioral Sciences - Medical Psychiatry
BioDr. Hoover graduated with a BS in Biology and a minor in Chemistry from Duke University. After his undergraduate studies, he joined the Leppla Laboratory at the National Institutes of Health as an Intramural Research Training Awardee. While there, he investigated the use of engineered anthrax toxin as a chemotherapeutic, and he graduated from the NIH Academy, with extensive coursework in health disparities. Then he returned to the Duke University School of Medicine, where he earned his MD in 2017. While in medical school, his interest in infectious disease evolved into curiosity about the gut-brain axis. He investigated gut sensation and its role in behavior using 3D electron microscopy, ultimately publishing a novel characterization of tuft cell ultrastructure.
Given his growing interest in behavior, Dr. Hoover pursued psychiatry residency at the MGH McLean program. During this time, he was accepted into the R-25 funded Physician Scientist Training Program and joined the Kahn Laboratory at the Joslin Diabetes Center. He employed an iPSC model to investigate the role of insulin signaling dysfunction in Alzheimer’s Disease pathogenesis. His clinical interests also began to focus on the intersection of medical and psychiatric disease. He served as a chief resident and won the Anne Alonso Award for Psychotherapy and the Residency Neuroscience Award. After residency, he was accepted into the MGH Consultation-Liaison Psychiatry Fellowship.
After graduating from fellowship in 2022, Dr. Hoover joined the Stanford University School of Medicine faculty as a Clinical Assistant Professor of Psychiatry. As part of the Medical Psychiatry division, he consults on hospitalized patients with psychiatric comorbidities within intensive care units and general medical and surgical floors. The interface between endocrinology and psychiatry remains a particular area of clinical and research interest, and he brings years of previous laboratory experience in this area to his clinical practice.
